Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Figg
W D
WD
Clinical Pharmacology Branch, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA.
Dawson
N
N
Middleman
M N
MN
Brawley
O
O
Lush
R M
RM
Senderowicz
A
A
Steinberg
S H
SH
Tompkins
A
A
Reed
E
E
Sartor
O
O
D000368:Aged; D000616:Aminoglutethimide / Q000008:administration & dosage*; D000726:Androgen Antagonists / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D019008:Drug Resistance, Neoplasm; D005485:Flutamide / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000503:physiopathology
D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D000616:Aminoglutethimide; D005485:Flutamide